390 related articles for article (PubMed ID: 17403708)
21. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
[TBL] [Abstract][Full Text] [Related]
22. The growing burden of antimicrobial resistance.
Hawkey PM
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i1-9. PubMed ID: 18684701
[TBL] [Abstract][Full Text] [Related]
23. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
Cafini F; Aguilar L; González N; Giménez MJ; Torrico M; Alou L; Sevillano D; Vallejo P; Prieto J
J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
[TBL] [Abstract][Full Text] [Related]
24. Critical shortage of new antibiotics in development against multidrug-resistant bacteria-Time to react is now.
Freire-Moran L; Aronsson B; Manz C; Gyssens IC; So AD; Monnet DL; Cars O;
Drug Resist Updat; 2011 Apr; 14(2):118-24. PubMed ID: 21435939
[TBL] [Abstract][Full Text] [Related]
25. Comparative analysis of antibiotic resistance characteristics of Gram-negative bacteria isolated from laying hens and eggs in conventional and organic keeping systems in Bavaria, Germany.
Schwaiger K; Schmied EM; Bauer J
Zoonoses Public Health; 2008 Sep; 55(7):331-41. PubMed ID: 18667026
[TBL] [Abstract][Full Text] [Related]
26. The current state of multidrug-resistant gram-negative bacilli in North America.
Nicasio AM; Kuti JL; Nicolau DP
Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
[TBL] [Abstract][Full Text] [Related]
27. Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens.
Cornaglia G; Rossolini GM
Clin Microbiol Infect; 2009 Mar; 15(3):218-23. PubMed ID: 19335369
[TBL] [Abstract][Full Text] [Related]
28. Novel antibiotics for the management of diabetic foot infections.
Omar NS; El-Nahas MR; Gray J
Int J Antimicrob Agents; 2008 May; 31(5):411-9. PubMed ID: 18155884
[TBL] [Abstract][Full Text] [Related]
29. Antimicrobial activity of phenothiazines.
Amaral L; Viveiros M; Molnar J
In Vivo; 2004; 18(6):725-31. PubMed ID: 15646813
[TBL] [Abstract][Full Text] [Related]
30. Polyamine effects on antibiotic susceptibility in bacteria.
Kwon DH; Lu CD
Antimicrob Agents Chemother; 2007 Jun; 51(6):2070-7. PubMed ID: 17438056
[TBL] [Abstract][Full Text] [Related]
31. Antimicrobial resistance of bacterial isolates from respiratory care wards in Taiwan: a horizontal surveillance study.
Kuo LC; Yu CJ; Kuo ML; Chen WN; Chang CK; Lin HI; Chen CC; Lu MC; Lin CH; Hsieh WF; Chen LW; Chou Y; Huang MS; Lee CH; Chen SC; Thai SL; Chen PC; Chen CH; Tseng CC; Chen YS; Hsiue TR; Hsueh PR
Int J Antimicrob Agents; 2008 May; 31(5):420-6. PubMed ID: 18358701
[TBL] [Abstract][Full Text] [Related]
32. Antibiotic resistance: how it arises, the current position and strategies for the future.
Perry C; Hall C
Nurs Times; 2009 Sep 15-21; 105(36):20-3. PubMed ID: 19835196
[TBL] [Abstract][Full Text] [Related]
33. [Calculated antibiotic therapy in gastroenterologic infections].
Braun RW
Praxis (Bern 1994); 2003 Aug; 92(33):1343-9. PubMed ID: 14502790
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of forty new phenothiazine derivatives for activity against intrinsic efflux pump systems of reference Escherichia coli, Salmonella Enteritidis, Enterococcus faecalis and Staphylococcus aureus strains.
Takács D; Cerca P; Martins A; Riedl Z; Hajós G; Molnár J; Viveiros M; Couto I; Amaral L
In Vivo; 2011; 25(5):719-24. PubMed ID: 21753124
[TBL] [Abstract][Full Text] [Related]
35. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance.
Jones RN; Kirby JT; Rhomberg PR
Diagn Microbiol Infect Dis; 2008 Jun; 61(2):203-13. PubMed ID: 18329835
[TBL] [Abstract][Full Text] [Related]
36. Bacterial resistance to antibiotics: active efflux and reduced uptake.
Kumar A; Schweizer HP
Adv Drug Deliv Rev; 2005 Jul; 57(10):1486-513. PubMed ID: 15939505
[TBL] [Abstract][Full Text] [Related]
37. Potential role of non-antibiotics (helper compounds) in the treatment of multidrug-resistant Gram-negative infections: mechanisms for their direct and indirect activities.
Martins M; Dastidar SG; Fanning S; Kristiansen JE; Molnar J; Pagès JM; Schelz Z; Spengler G; Viveiros M; Amaral L
Int J Antimicrob Agents; 2008 Mar; 31(3):198-208. PubMed ID: 18180147
[TBL] [Abstract][Full Text] [Related]
38. Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections.
Critchley IA; Green LS; Young CL; Bullard JM; Evans RJ; Price M; Jarvis TC; Guiles JW; Janjic N; Ochsner UA
J Antimicrob Chemother; 2009 May; 63(5):954-63. PubMed ID: 19258353
[TBL] [Abstract][Full Text] [Related]
39. New trends in pharmacogenomic strategies against resistance development in microbial infections.
Ohlsen K; Dandekar G; Schwarz R; Dandekar T
Pharmacogenomics; 2008 Nov; 9(11):1711-23. PubMed ID: 19018725
[TBL] [Abstract][Full Text] [Related]
40. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.
Draghi DC; Benton BM; Krause KM; Thornsberry C; Pillar C; Sahm DF
J Antimicrob Chemother; 2008 Jul; 62(1):116-21. PubMed ID: 18424792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
